CLLS
$3.45
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications.
Intraday
Recent News
European Equities Traded in the US as American Depositary Receipts Decline in Friday Trading
European equities traded in the US as American depositary receipts were lower late Friday morning, d
European Equities Traded in US as ADRs Slump in Thursday Trading
European equities traded in the US as American depositary receipts slumped late Thursday morning wit
Poolbeg Pharma adds CAR-T therapy expert to scientific advisory board
Poolbeg Pharma PLC (AIM:POLB, OTC:POLBF, FRA:POLBF), the AIM-listed clinical-stage biopharmaceutical company, has appointed Dr Adrian Kilcoyne to its Scientific Advisory Board, bringing more than 20 years of oncology and immunology drug development experience to the company. Kilcoyne is...
European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading
European equities traded in the US as American depositary receipts late Tuesday morning, rising 1.12
European Equities Traded in the US as American Depositary Receipts Slide in Thursday Trading
European equities traded in the US as American depositary receipts were sliding late Thursday mornin